Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001172661-25-003264
Filing Date
2025-08-14
Accepted
2025-08-14 08:48:03
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9615
  Complete submission text file 0001172661-25-003264.txt   11360
Mailing Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BOULEVARD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 6508505070
Maze Therapeutics, Inc. (Subject) CIK: 0001842295 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-94841 | Film No.: 251214642
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 200 GREENWICH AVENUE 3RD FLOOR GREENWICH CT 06830
Business Address 200 GREENWICH AVENUE 3RD FLOOR GREENWICH CT 06830 2034090812
Deep Track Capital, LP (Filed by) CIK: 0001856083 (see all company filings)

EIN.: 853360885 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A